Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Pharmacokinetics of pyrazinamide during the initial phase of tuberculous meningitis treatment.

Stemkens R, Litjens CHC, Dian S, Ganiem AR, Yunivita V, van Crevel R, Te Brake LHM, Ruslami R, Aarnoutse RE.

Int J Antimicrob Agents. 2019 Jun 13. pii: S0924-8579(19)30163-3. doi: 10.1016/j.ijantimicag.2019.06.010. [Epub ahead of print]

PMID:
31202922
2.

High-dose rifampicin in tuberculosis: Experiences from a Dutch tuberculosis centre.

Seijger C, Hoefsloot W, Bergsma-de Guchteneire I, Te Brake L, van Ingen J, Kuipers S, van Crevel R, Aarnoutse R, Boeree M, Magis-Escurra C.

PLoS One. 2019 Mar 14;14(3):e0213718. doi: 10.1371/journal.pone.0213718. eCollection 2019.

3.

Conflicting Findings on an Intermediate Dose of Rifampicin for Pulmonary Tuberculosis.

Te Brake LHM, Boeree MJ, Aarnoutse RE.

Am J Respir Crit Care Med. 2019 May 1;199(9):1166-1167. doi: 10.1164/rccm.201811-2101LE. No abstract available.

4.

Protein binding of rifampicin is not saturated when using high-dose rifampicin.

Litjens CHC, Aarnoutse RE, van Ewijk-Beneken Kolmer EWJ, Svensson EM, Colbers A, Burger DM, Boeree MJ, Te Brake LHM; PanACEA-MAMS-TB-01 Team .

J Antimicrob Chemother. 2019 Apr 1;74(4):986-990. doi: 10.1093/jac/dky527.

PMID:
30597025
5.

Intensified antibiotic treatment of tuberculosis meningitis.

Cresswell FV, Te Brake L, Atherton R, Ruslami R, Dooley KE, Aarnoutse R, Van Crevel R.

Expert Rev Clin Pharmacol. 2019 Mar;12(3):267-288. doi: 10.1080/17512433.2019.1552831. Epub 2019 Feb 12. Review.

PMID:
30474434
6.

Double-Blind, Randomized, Placebo-Controlled Phase II Dose-Finding Study To Evaluate High-Dose Rifampin for Tuberculous Meningitis.

Dian S, Yunivita V, Ganiem AR, Pramaesya T, Chaidir L, Wahyudi K, Achmad TH, Colbers A, Te Brake L, van Crevel R, Ruslami R, Aarnoutse R.

Antimicrob Agents Chemother. 2018 Nov 26;62(12). pii: e01014-18. doi: 10.1128/AAC.01014-18. Print 2018 Dec.

7.

Rifampicin Alters Metformin Plasma Exposure but Not Blood Glucose Levels in Diabetic Tuberculosis Patients.

Te Brake LHM, Yunivita V, Livia R, Soetedjo N, van Ewijk-Beneken Kolmer E, Koenderink JB, Burger DM, Santoso P, van Crevel R, Alisjahbana B, Aarnoutse RE, Ruslami R; on behalf of the TANDEM Consortium.

Clin Pharmacol Ther. 2019 Mar;105(3):730-737. doi: 10.1002/cpt.1232. Epub 2018 Oct 29.

PMID:
30222857
8.

High dose oral and intravenous rifampicin for improved survival from adult tuberculous meningitis: a phase II open-label randomised controlled trial (the RifT study).

Cresswell FV, Ssebambulidde K, Grint D, Te Brake L, Musabire A, Atherton RR, Tugume L, Muzoora C, Lukande R, Lamorde M, Aarnoutse R, Meya D, Boulware DR, Elliott AM.

Wellcome Open Res. 2018 Jul 10;3:83. doi: 10.12688/wellcomeopenres.14691.1. eCollection 2018.

9.

Assessment of the Additional Value of Verapamil to a Moxifloxacin and Linezolid Combination Regimen in a Murine Tuberculosis Model.

Pieterman ED, Te Brake LHM, de Knegt GJ, van der Meijden A, Alffenaar JC, Bax HI, Aarnoutse RE, de Steenwinkel JEM.

Antimicrob Agents Chemother. 2018 Aug 27;62(9). pii: e01354-18. doi: 10.1128/AAC.01354-18. Print 2018 Sep.

10.

The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis.

Svensson EM, Svensson RJ, Te Brake LHM, Boeree MJ, Heinrich N, Konsten S, Churchyard G, Dawson R, Diacon AH, Kibiki GS, Minja LT, Ntingiya NE, Sanne I, Gillespie SH, Hoelscher M, Phillips PPJ, Simonsson USH, Aarnoutse R.

Clin Infect Dis. 2018 Jun 18;67(1):34-41. doi: 10.1093/cid/ciy026.

11.

Determination of protein-unbound, active rifampicin in serum by ultrafiltration and Ultra Performance Liquid Chromatography with UV detection. A method suitable for standard and high doses of rifampicin.

van Ewijk-Beneken Kolmer EWJ, Teulen MJA, van den Hombergh ECA, van Erp NE, Te Brake LHM, Aarnoutse RE.

J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Sep 15;1063:42-49. doi: 10.1016/j.jchromb.2017.08.004. Epub 2017 Aug 4.

12.

Pharmacokinetics, Tolerability, and Bacteriological Response of Rifampin Administered at 600, 900, and 1,200 Milligrams Daily in Patients with Pulmonary Tuberculosis.

Aarnoutse RE, Kibiki GS, Reither K, Semvua HH, Haraka F, Mtabho CM, Mpagama SG, van den Boogaard J, Sumari-de Boer IM, Magis-Escurra C, Wattenberg M, Logger JGM, Te Brake LHM, Hoelscher M, Gillespie SH, Colbers A, Phillips PPJ, Plemper van Balen G, Boeree MJ; PanACEA Consortium.

Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e01054-17. doi: 10.1128/AAC.01054-17. Print 2017 Nov.

13.

The Role of Efflux Pumps in Tuberculosis Treatment and Their Promise as a Target in Drug Development: Unraveling the Black Box.

Te Brake LHM, de Knegt GJ, de Steenwinkel JE, van Dam TJP, Burger DM, Russel FGM, van Crevel R, Koenderink JB, Aarnoutse RE.

Annu Rev Pharmacol Toxicol. 2018 Jan 6;58:271-291. doi: 10.1146/annurev-pharmtox-010617-052438. Epub 2017 Jul 17. Review.

PMID:
28715978
14.

Moxifloxacin Is a Potent In Vitro Inhibitor of OCT- and MATE-Mediated Transport of Metformin and Ethambutol.

Te Brake LH, van den Heuvel JJ, Buaben AO, van Crevel R, Bilos A, Russel FG, Aarnoutse RE, Koenderink JB.

Antimicrob Agents Chemother. 2016 Nov 21;60(12):7105-7114. Print 2016 Dec.

15.

Inhibitory potential of tuberculosis drugs on ATP-binding cassette drug transporters.

Te Brake LH, Russel FG, van den Heuvel JJ, de Knegt GJ, de Steenwinkel JE, Burger DM, Aarnoutse RE, Koenderink JB.

Tuberculosis (Edinb). 2016 Jan;96:150-7. doi: 10.1016/j.tube.2015.08.004. Epub 2015 Oct 9.

PMID:
26682943
16.

Exposure to total and protein-unbound rifampin is not affected by malnutrition in Indonesian tuberculosis patients.

te Brake LH, Ruslami R, Later-Nijland H, Mooren F, Teulen M, Apriani L, Koenderink JB, Russel FG, Burger DM, Alisjahbana B, Wieringa F, van Crevel R, Aarnoutse RE.

Antimicrob Agents Chemother. 2015;59(6):3233-9. doi: 10.1128/AAC.03485-14. Epub 2015 Mar 23.

17.

Pharmacokinetic/pharmacodynamic analysis of an intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis.

Te Brake L, Dian S, Ganiem AR, Ruesen C, Burger D, Donders R, Ruslami R, van Crevel R, Aarnoutse R.

Int J Antimicrob Agents. 2015 May;45(5):496-503. doi: 10.1016/j.ijantimicag.2014.12.027. Epub 2015 Feb 7.

PMID:
25703312
18.

A category approach to predicting the developmental (neuro) toxicity of organotin compounds: the value of the zebrafish (Danio rerio) embryotoxicity test (ZET).

Beker van Woudenberg A, Wolterbeek A, Te Brake L, Snel C, Menke A, Rubingh C, de Groot D, Kroese D.

Reprod Toxicol. 2013 Nov;41:35-44. doi: 10.1016/j.reprotox.2013.06.067. Epub 2013 Jun 21.

PMID:
23796951

Supplemental Content

Loading ...
Support Center